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Abstract Migraine attacks are believed to involve acti-
vation of the trigeminovascular system and trigeminal-
parasympathetic reflex, which is mediated through the
sphenopalatine ganglion (SPG). An implantable SPG neu-
rostimulator has been developed to apply on-demand SPG
stimulation for the treatment of severe primary headache.
The neurostimulator is implanted via an oral incision and
placed along the maxilla, with the lead placed at the SPG.
The neurostimulator contains no battery and is powered
and controlled via a handheld remote controller. The
potential interest of patients with high-frequency, high-
disability migraine in having a SPG neurostimulator
implanted to treat migraine is unknown. We aimed to
evaluate patient interest to undergo such an implantation
procedure and to participate in a clinical investigation of
on-demand SPG stimulation for migraine by conducting a
survey at the Ghent University Hospital in 41 migraineurs.
Seventy-seven percent (77%) of subjects expressed an
interest in participating in a clinical investigation requiring
implantation of a SPG neurostimulator when headache
frequency and severity were considered and 69% when
pain relief experienced with current migraine treatment
was considered. Preventive and acute medications were
used in 64 and 95% of the subjects, respectively, and
provided a reported reduction of headache frequency,
duration and pain. However, acute medications were
frequently associated with headache recurrence and both-
ersome side effects. Results indicate that a majority of
high-frequency, high-disability migraineurs, many of
whom achieve pain relief with their current medications,
have an interest in participating in a clinical investigation
of an implantable SPG neurostimulator for the treatment of
migraine headache.
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Introduction
The sphenopalatine ganglion (SPG) is an extracranial
parasympathetic neural structure located in the pterygo-
palatine fossa. Migraine pain is believed to result from
activation of the trigeminovascular system along with a
trigeminal-parasympathetic reflex arc, which is mediated
through the SPG [1, 2]. Cranial autonomic symptoms,
which can be unilateral, are often associated with migraine
headaches. These features are present in between 30 and
70% of migraine patients and include conjunctival injec-
tion, lacrimation, nasal congestion, and rhinorrhea [3].
These symptoms are the result of activation of the cranial
parasympathetic system, and are believed to be due to
activation of the trigeminal afferent arm of the trigeminal-
parasympathetic reflex [4].
SPG interventions have been used for over 100 years to
treat headache pain [5]. These SPG procedures include
pharmacological blocks [6], lesional and non-lesional
ablations [7] and surgery [8]. Despite purposefully dam-
aging or destroying the SPG as part of the therapy, results
have been good with minimal side effects, although the
procedures have not provided permanent headache relief.
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Therefore, the potential of electrical stimulation of the SPG
has been explored in pilot studies for acute treatment of
cluster and migraine headaches using a temporary electrode
[9, 10]. More recently, on-demand SPG stimulation for the
treatment of chronic cluster headache has been evaluated in
the Pathway CH-1 study using a miniaturized neurostimu-
lator developed by Autonomic Technologies, Inc. (ATI).
The neurostimulator is implanted through a gingival buccal
incision using standard oral surgery techniques and placed
along the maxilla with the lead located at the SPG within the
pterygopalatine fossa. Following implantation, a ‘‘titration’’
period allows for refinement of stimulation settings. During
the experimental period, headaches were randomized to one
of three stimulation doses, including full-, sub-perception
and placebo stimulation.
The potential interest of patients with high-frequency,
high-disability migraine in undergoing implantation of a
SPG neurostimulator to treat migraine headache is unknown.
A multi-center clinical investigation, the Pathway M-1 trial,
is underway in Europe to evaluate both the acute and pre-
ventive effects of on-demand SPG stimulation. We aimed to
evaluate patient interest in undergoing such an implantation
procedure and participation in a clinical investigation of on-
demand SPG stimulation for migraine.
Methods
A patient survey was conducted in 41 migraine patients at the
Ghent University Hospital. Patients were required to have a
MIDAS score of III to IV or a HIT-6 score greater than 56, to
have 2–15 migraine pain days per month and to not have
medication-overuse headache. Subjects were asked to con-
sider their headache frequency and severity and their satis-
faction with their current migraine treatment and to evaluate
their willingness to undergo implantation of a neurostimulator
for a clinical evaluation of SPG stimulation for migraine.
Patients were provided with general information
regarding methods for using the ATI Neurostimulation
System including that the neurostimulator is powered and
controlled by holding a remote controller to the face
(Fig. 1b). The implantation procedure was described as
being similar to other types of oral surgery and requiring a
few weeks to heal. Specific procedure-related adverse
events were not provided. Specifically, patients were
informed that the neurostimulator would be implanted
through the mouth and placed behind the cheekbone
(Fig. 1a), would not be visible after implant and would
have no battery and thus would not require replacement,
though if needed, could be removed using local anesthetic.
The survey was designed to assess the percentage of
attacks expected to be adequately treated in order for the
patient to consider participation in a clinical investigation,
thus, information regarding expectations for pain relief was
not provided.
Results
The subject population (Tables 1, 2) for the survey con-
sisted largely of female high-frequency, high-disability
episodic migraineurs with a high percentage of associated
migraine symptoms. Subjects were recruited from the
Outpatient Neurology Clinic of the Ghent University
Hospital. Of the 41 subjects surveyed, 64% currently used
preventive medication for their migraines, which were
reported to reduce both migraine frequency (65%) and
duration of the attacks (52%), but caused bothersome side
effects in some subjects (24%). Thirty-nine subjects (95%)
used acute medications which provided pain relief (75%)
and pain freedom (68%), but were frequently associated
with both headache recurrence (93%) and bothersome side
effects (69%).
Fig. 1 a Diagram showing the location of the implant behind the
cheekbone. b Diagram showing how the remote controller is held
over the cheek to control the activation of the neurostimulator
Table 1 Subject population
Gender Female 79%
Age 37 (range 18–76)
Years of migraines 17 (range 2–66)
Frequency Attacks/month: 7 (range 2–15)
Days/month: 11 (range 4–20)







I: 2 III: 13
II: 0 IV: 26
HIT-6
64 (range 57–72)
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The majority of subjects used both preventive and acute
medications. Although these medications were reported to
reduce migraine frequency, duration and pain, the majority
of subjects indicated they would consider participating in
an investigation of a SPG neurostimulator for migraine.
Specifically, given headache frequency/severity, and given
the pain relief experienced with current migraine treatment,
77 and 69% of subjects, respectively, indicated a willing-
ness to consider participating in a clinical investigation
requiring implantation of a SPG neurostimulator. Of the
subjects who would consider receiving an implant and
participating in the study, 100% expected the therapy to
treat at least 50%, and 81% expected the therapy to treat at
least 75% of their migraines. Thus, the survey indicated an
expectation that an implanted device to treat migraine
should treat a majority of migraine attacks.
Conclusion
Sphenopalatine ganglion stimulation using an implanted, on-
demand neurostimulator is a novel, promising therapy option
for migraine sufferers, although the ability of SPG stimula-
tion to provide acute relief of migraine pain has not yet been
demonstrated. Results of the survey conducted at the Ghent
University Hospital indicate that a majority of high-fre-
quency, high-disability migraineurs, many of whom achieve
pain relief with their current medications, are willing to
undergo implantation of a SPG neurostimulator and partic-
ipate in a clinical investigation of SPG stimulation for the
treatment of migraine headache, expecting a very efficacious
non-pharmacological therapy alternative. Patient expecta-
tions regarding pain relief should be assessed and discussed
prior to enrollment in the study. Detailed information on
potential side effects and adverse events will further influ-
ence a patient’s decision to participate, but was not included
in this survey.
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52% Reduction in headache duration 68% Pain freedom
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69% Bothersome side effects
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